Diabetic injection for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Diabetic Injections for Weight Loss
Introduction to Diabetic Injections and Weight Loss
Diabetic injections, particularly those involving glucagon-like peptide-1 (GLP-1) receptor agonists, have shown promise not only in managing blood glucose levels but also in promoting weight loss. This dual benefit is particularly valuable for patients with type 2 diabetes, who often struggle with obesity. This article synthesizes recent research on various injectable treatments that aid in weight loss for diabetic patients.
GLP-1 Receptor Agonists: Liraglutide and Noiiglutide
Liraglutide for Weight Management
Liraglutide, a GLP-1 analogue, has been extensively studied for its weight loss benefits. In a 56-week trial involving 3731 non-diabetic patients with a BMI of at least 30, liraglutide at a dose of 3.0 mg daily resulted in significant weight loss. Patients in the liraglutide group lost an average of 8.4 kg compared to 2.8 kg in the placebo group. Additionally, 63.2% of patients in the liraglutide group lost at least 5% of their body weight, and 33.1% lost more than 10%.
Noiiglutide in Obese Chinese Adults
Noiiglutide, another GLP-1 receptor agonist, was tested in a 24-week trial involving 254 obese Chinese adults without diabetes. The study found that noiiglutide significantly reduced body weight across all dosage levels, with reductions ranging from 8.03 to 8.50 kg compared to 3.65 kg in the placebo group. A higher proportion of participants in the noiiglutide groups achieved weight loss of at least 5% and 10% compared to the placebo group.
Dual Agonists: MEDI0382 and KBP-066
MEDI0382 for Glycemic Control and Weight Loss
MEDI0382, a dual agonist for GLP-1 and glucagon receptors, was evaluated in a study involving 112 patients with type 2 diabetes. The study demonstrated that MEDI0382 significantly reduced both blood glucose levels and body weight. Patients in the MEDI0382 group experienced a mean weight reduction of 3.84 kg compared to 1.70 kg in the placebo group.
KBP-066: Dual Amylin and Calcitonin Receptor Agonist
KBP-066, a dual amylin and calcitonin receptor agonist, was tested in obese rats and showed significant weight loss across a broad dose range. The study indicated that higher doses might further improve insulin action, suggesting potential benefits for diabetic patients.
Empagliflozin: SGLT2 Inhibitor
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was studied in obese patients with type 2 diabetes inadequately controlled on multiple daily injections of insulin. The study found that empagliflozin significantly improved glycemic control and reduced weight by approximately 2.4 to 2.5 kg compared to placebo.
Pramlintide: Amylin Analogue
Pramlintide, an amylin analogue, was shown to reduce energy intake and enhance satiety in both diabetic and non-diabetic obese subjects. In a study involving insulin-treated men with type 2 diabetes and non-diabetic obese men, pramlintide reduced energy intake by 23% and 16%, respectively, leading to significant weight loss.
Real-World Data on GLP-1 RAs
A retrospective cohort study in the UK assessed the real-world effectiveness of GLP-1 receptor agonists. The study found that 33.4% of patients achieved at least 5% weight loss at 12 months, and 43.5% at 24 months. However, adherence to the treatment was suboptimal, with a significant proportion of patients discontinuing the therapy within the first year.
Conclusion
Injectable treatments for type 2 diabetes, particularly GLP-1 receptor agonists like liraglutide and noiiglutide, as well as dual agonists like MEDI0382 and KBP-066, have shown significant promise in promoting weight loss. These treatments not only improve glycemic control but also help in managing obesity, a common comorbidity in diabetic patients. However, real-world adherence to these treatments remains a challenge, highlighting the need for additional support to ensure long-term benefits.
Sources and full results
Most relevant research papers on this topic